Lumida
/SNWV
⌘K
SANUWAVE Health Inc

SANUWAVE Health Inc

SNWV
$4.66USD↓-4.31%-0.21 today

MARKET CAP

40.1M

P/E (TTM)

4.9x

FWD P/E

3.4x

DAY RANGE

$5 – $5

52W RANGE

$5
$45

AI Summary

Stalk
TrimMedium

In a Stage 4 decline, both medium- and long-term biases remain bearish. Despite an extreme oversold bounce, price is still below the downward-sloping 9/21 EMAs without any clear rejection at resistance levels. With no definitive short-side trigger, execution should be deferred, awaiting a pullback into the EMA zone for a structurally sound short entry.

  • ↑UltraMist system taps growing wound care demand and rising consumable sales
  • ↑Low debt supports sustained R&D and marketing investments
  • ↓Q2 revenue $9.6–$9.8M fell 3–5% from prior year
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

SANUWAVE Health, Inc. (SNWV) is an emerging medical device company specializing in directed energy products, specifically the UltraMist system, which is designed for wound care treatment. Operating within the healthcare and medical technology sectors, SANUWAVE is aiming to carve out a niche in the rapidly growing wound care market, driven by an increasing demand for innovative treatment options. Despite recent financial challenges, the company has focused on expanding its portfolio and improving operational efficiencies.

Bull says

  • ↑UltraMist system taps growing wound care demand and rising consumable sales
  • ↑Low debt supports sustained R&D and marketing investments
  • ↑Positive interest-rate sensitivity may lower financing costs
  • ↑Institutional 13F ownership signals professional investor confidence
  • ↑Dividend yield of 0.84% appeals to income-focused investors
  • ↑August earnings call offers catalyst to reset investor expectations

Bear says

  • ↓Q2 revenue $9.6–$9.8M fell 3–5% from prior year
  • ↓Negative earnings yield and low profitability deter growth investors
  • ↓Analysts’ forecasts cut amid high negative earnings revisions
  • ↓Weak momentum indicators signal continued downward pressure
  • ↓Stock down 79.6% YTD reflects poor market sentiment
  • ↓Small market cap amplifies volatility and limits scalability

Earnings Call · Q4 2024 · Mgmt. Guidance

Updated 05-02-2026bullish

Transcript signals

Bull points

  • We continue to execute on our goal of rapid, profitable growth.
  • Revenue for the three months ended December 31st, 2024 totaled $10.3 million, an increase of 47% as compared to $7 million for the same period of 2023.
  • Gross margin as a percentage of revenue amounted to 77.9% for the three months ended December 31st, 2024 versus 69.1% for the same period last year.

Bear points

  • Net loss for the three months ended December 31st, 2024 was $12.7 million compared to net income of $18.2 million for the same period in 2023.
  • EBITDA for the three months ended December 31st, 2024 was negative $9.7 million.
Read full transcript analysis ›